What are the benefits and risks of being in this study?

One benefit of taking part in this study is that your health will be monitored frequently. However, there is no guarantee that this study will improve your health. It may stay the same or it may get worse. Also, as with all drugs, the study drugs may cause side effects. We may be able to prevent or manage some of these and many go away quickly. Any study has risks, which may include things that could make you feel sick or uncomfortable or could cause harm. The study staff will review potential risks before study enrollment.

Can I decide not to be in the study?

Taking part in a clinical study is voluntary. If you are eligible to enroll, you may choose to join the study but leave at a later date for any reason at any time. Regardless of whether you choose to enroll or leave the study early, your future healthcare won't be affected.

How can I learn more about this study?

To learn more please visit
www.gskdestinystudy.com
or scan the code below.

DESTINY

217013_advocacy_PAG_patient_FAQ_brochure_v1.0_09Feb2022_English

NOW ENROLLING:

The DESTINY Study

for adults with uncontrolled hypereosinophilic syndrome (HES)

A quick reference guide for potential participants in the DESTINY study

Thank you for your interest in the DESTINY study. This fact sheet provides more details about the study so you can decide if you want to find out more information. If you have questions or would like to know more, please visit **www.gskdestinystudy.com** or scan the code on the back cover.

DESTINY

What is this study?

The DESTINY clinical research study is looking for participants 18 years of age or older with a diagnosis of hypereosinophilic syndrome (HES) and a history of 2 or more flares within the past 12 months. Study doctors are testing an investigational drug given as injections to find out if it works as compared to a placebo and to determine the investigational drug's safety in patients with HES.

Some participants will receive the investigational drug (depemokimab) and some participants will receive a placebo. Both study groups will also receive standard of care HES therapy as prescribed by a doctor.

An investigational drug is one that is not approved for use by the general public. Placebo is a substance that looks like the study drug but has no active drug in it. Your study group assignment is blinded, meaning you and your study doctor will not know which study group you are in.

Who is this study enrolling?

Approximately 120 participants will be assigned to a study drug group in this study. You may qualify for this study if you:

- Are at least 18 years of age or older
- Are diagnosed with HES
- Have a history of 2 or more flares within the past 12 months

Why is this study important?

HES is a rare, underdiagnosed condition that occurs when you have high numbers of eosinophils. Eosinophils are white blood cells that play an important role in your immune system. Inflammatory tissue damage and dysfunction can occur when eosinophils are overproduced for prolonged periods of time.

People living with HES are in need of more effective therapies for this condition. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug (depemokimab) administered every 6 months compared to a placebo administered every 6 months.

How are the study drugs being tested?

In this study, you will be assigned to a study drug group. You will receive either:

- An investigational drug (depemokimab) given as injections every 6 months (in addition to your standard HES therapy as prescribed by your doctor)

OR

- A placebo drug given as injections every 6 months (in addition to your standard HES therapy as prescribed by your doctor)

You will not be told which group you are in.

How long will I be in this study?

After the screening visit, you will receive two injections every 6 months. This study will consist of at least 18 visits (in-clinic or remotely) over a period of up to 56 weeks plus a follow-up phone call 4 weeks after the final visit (additional visits may be necessary for HES flares).

How long is each study visit?

The duration of each visit can vary depending on the specific needs of each patient. Some visits may also be conducted at your home. Please ask your doctor for information about the duration of each visit based on your individual requirements.

How will my health be monitored in this study?

During the study, you will visit the study site regularly for health checks and several types of tests and assessments. These may include:

- Physical exams
- Vital signs measurements (body temperature, blood pressure, and heart rate)
- Electrocardiograms (to measure the electrical activity of the heart)
- Echocardiogram (to check that your heart's valves and chambers are working properly)
- Spirometry (breathing tests to see how well your lungs work)
- Blood and urine tests
- Questionnaires from study staff and in the eDiary (at Visit 1, you will be trained on how to use the eDiary at home to complete some questionnaires)

Not all these activities will occur at every visit.